脂质调节剂市场- 依类型（他汀类药物[品牌、组合]、非他汀类药物[纤维酸衍生物、胆汁酸]）、依适应症（高胆固醇血症、冠状动脉疾病）、依给药途径、配销通路与预测，2024 年- 2032

由于不健康饮食、久坐的生活方式和人口老化等因素，心臟病和中风等心血管疾病的盛行率不断上升，预计2024年至2032年期间，脂质调节剂市场规模将以3.8%的复合年增长率成长。根据 CDC 的数据，美国每 40 秒就有一人心臟病发作，每年约有 805,000 人心臟病发作。脂质调节剂是帮助控制胆固醇水平并降低心血管事件风险的药物。

医疗保健专业人员和患者对血脂管理重要性的认识不断提高，导致诊断和治疗率提高。此外，旨在促进心血管健康的有利政府倡议，例如公共卫生运动、筛检计画和调脂药物的报销政策，将在推动市场成长方面发挥重要作用。这些措施有助于提高意识，改善医疗保健服务的可近性，并减轻心血管疾病的经济负担，进一步鼓励采用血脂调节剂。

整个市场根据类型、适应症、配销通路、给药途径和区域进行分类。

从给药途径来看，注射型脂质调节剂产业预计到2032 年复合年增长率将达到3.1%。治疗选择血脂水平。此外，注射製剂通常提供更一致和可预测的吸收，从而改善治疗结果和患者依从性。

从配销通路来看，2024年-2032年，网路药局血脂调节剂市场将录得4.5%的成长率。网路药局提供的便利性和可近性使患者更容易获得调脂药物，从而提高治疗的依从性和依从性。患者可以轻鬆地在线订购处方并将其送到家门口，同时无需频繁前往传统的实体药局。此外，线上药局提供有竞争力的价格和折扣，使血脂调节剂对患者来说更实惠和有吸引力。

由于心血管疾病和肥胖和久坐生活方式等相关危险因子的盛行率不断增加，欧洲脂质调节剂产业在2024年至2032年间将以4.4%的复合年增长率快速扩张。严格的医疗保健法规和指南强调胆固醇管理的重要性，透过促进脂质疾病的早期诊断和治疗，促进了对脂质调节剂的需求。药品研发的不断进步，加上新型调脂疗法的推出，可能会进一步刺激区域产业扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 心血管疾病盛行率增加
    • 药物开发的进展
    • 老年人口不断增加
  • 产业陷阱与挑战
    • 与脂质调节剂相关的副作用
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2018 - 2032

• 主要趋势
• 他汀类药物
  • 品牌他汀类药物
  • 他汀类药物组合
  • 通用他汀类药物
• 非他汀类药物
  • 纤维酸衍生物
  • 胆汁酸螯合剂
  • 依折麦布
  • 烟碱酸衍生物
  • PCSK9抑制剂
  • 其他非他汀类药物

第 6 章：市场估计与预测：按指标划分，2018 年 - 2032 年

• 主要趋势
• 高胆固醇血症
• 高三酸甘油脂血症
• 冠状动脉疾病
• 其他适应症

第 7 章：市场估计与预测：按管理途径，2018 年 - 2032 年

• 主要趋势
• 口服
• 可注射

第 8 章：市场估计与预测：按配销通路，2018 年 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 10 章：公司简介

• AbbVie Inc
• Amgen Inc.
• AstraZeneca plc
• Bristol-Myers Squibb
• Dr. Reddy's Laboratories Ltd.
• Merck & Co.
• Novartis AG
• Pfizer, Inc.
• Sanofi
• Teva Pharmaceuticals

Lipid regulators market size is anticipated to grow at 3.8% CAGR between 2024 and 2032, driven by the increasing prevalence of cardiovascular diseases, such as heart attacks and strokes, due to factors like unhealthy diets, sedentary lifestyles, and aging populations. As per CDC, every 40 seconds, an individual in the U.S. experiences a heart attack, totaling approximately 805,000 people annually. Lipid regulators are medications that help manage cholesterol levels and reduce the risk of cardiovascular events.

The rising awareness about the importance of lipid management among healthcare professionals and patients has led to increased diagnosis and treatment rates. Moreover, favorable government initiatives aimed at promoting cardiovascular health, such as public health campaigns, screening programs, and reimbursement policies for lipid-regulating medications will play a significant role in driving market growth. These initiatives help raise awareness, improve access to healthcare services, and reduce the economic burden of cardiovascular diseases, further encouraging the adoption of lipid regulators.

The overall market is classified based on type, indication, distribution channel, route of administration and region.

By route of administration, the lipid regulators industry from the injectable segment is anticipated to witness 3.1% CAGR through 2032. Injectable lipid regulators offer a convenient and effective treatment option for patients who may have difficulty adhering to oral therapies or who require rapid and precise control of lipid levels. Additionally, injectable formulations often provide more consistent and predictable absorption, leading to improved therapeutic outcomes and patient compliance.

In terms of distribution channel, the lipid regulators market from the online pharmacies segment will record 4.5% growth rate during 2024 -2032. The convenience and accessibility offered by online pharmacies makes it easier for patients to access lipid-regulating medications, thereby increasing treatment adherence and compliance. Patients can conveniently order their prescriptions online and have them delivered to their doorstep while eliminating the need for frequent visits to traditional brick-and-mortar pharmacies. Additionally, online pharmacies offer competitive pricing and discounts, making lipid regulators more affordable and attractive to patients.

Europe lipid regulators industry will witness rapid expansion at 4.4% CAGR between 2024 and 2032, attributed to the increasing prevalence of cardiovascular diseases and related risk factors, such as obesity and sedentary lifestyles. Stringent healthcare regulations and guidelines emphasizing the importance of cholesterol management are contributing to the need for lipid regulators by promoting early diagnosis and treatment of lipid disorders. Rising advancements in pharmaceutical R&D coupled with the introduction of novel lipid-regulating therapies may further stimulate the regional industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cardiovascular diseases
    • 3.2.1.2 Advancements in drug development
    • 3.2.1.3 Growing geriatric population
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with lipid regulators
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Statins
  • 5.2.1 Branded statins
  • 5.2.2 Statin combination
  • 5.2.3 Generic statins
• 5.3 Non-statins
  • 5.3.1 Fibric-acid derivatives
  • 5.3.2 Bile-acid sequestrants
  • 5.3.3 Ezetimibe
  • 5.3.4 Nicotinic acid derivatives
  • 5.3.5 PCSK9 inhibitors
  • 5.3.6 Other non-statins

Chapter 6 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hypercholesterolemia
• 6.3 Hypertriglyceridemia
• 6.4 Coronary artery disease
• 6.5 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc
• 10.2 Amgen Inc.
• 10.3 AstraZeneca plc
• 10.4 Bristol-Myers Squibb
• 10.5 Dr. Reddy's Laboratories Ltd.
• 10.6 Merck & Co.
• 10.7 Novartis AG
• 10.8 Pfizer, Inc.
• 10.9 Sanofi
• 10.10 Teva Pharmaceuticals